Sanofi (MEX:SAN1N) Construction In Progress: MXN75,586 Mil (As of Dec. 2025)


MEX:SAN1N Sanofi SA MEX:SAN1N
72 GF Score
Price MXN1,525.85
GF Value MXN2,212.65
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Sanofi Construction In Progress?

Sanofi MEX:SAN1N 72 Construction In Progress is MXN75,586 Mil as of Dec. 2025. GuruFocus rates MEX:SAN1N with a GF Score™ of 72/100 and a GF Value™ of MXN2,212.65 (Possible Value Trap). The stock has 2 warning signs investors should review.

Sanofi's quarterly construction in progress declined from Dec. 2024 (MXN78,029 Mil) to Jun. 2025 (MXN0 Mil) but then increased from Jun. 2025 (MXN0 Mil) to Dec. 2025 (MXN75,586 Mil).

Sanofi's annual construction in progress increased from Dec. 2023 (MXN63,843 Mil) to Dec. 2024 (MXN78,029 Mil) but then declined from Dec. 2024 (MXN78,029 Mil) to Dec. 2025 (MXN75,586 Mil).

Sanofi Construction In Progress Historical Data

* Premium members only.

The historical data trend for Sanofi's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Construction In Progress Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71,787.41 61,875.02 63,843.16 78,028.71 75,585.99

Sanofi Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63,843.16 0.00 78,028.71 0.00 75,585.99
MEX:SAN1N
72GF Score
Sanofi SA MEX:SAN1N
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of MXN75,586 Mil mean?
Sanofi (MEX:SAN1N) has a Construction In Progress of MXN75,586 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Sanofi and its competitors.
Is Sanofi's Construction In Progress too high?
Sanofi's current Construction In Progress is MXN75,586 Mil. Overall, Sanofi has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Construction In Progress compare to LLY and JNJ?
Sanofi's Construction In Progress of MXN75,586 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Sanofi and its competitors. Sanofi's current Construction In Progress is MXN75,586 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (MEX:SAN1N) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,212.65, compared to a current price of MXN1,525.85 — trading 31% below its estimated fair value. The current Construction In Progress is MXN75,586 Mil. Sanofi's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Sanofi (MEX:SAN1N), the current Construction In Progress is MXN75,586 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (MEX:SAN1N) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of MXN1,525.85 is trading 31% below its estimated GF Value™ of MXN2,212.65. GuruFocus considers Sanofi to be Possible Value Trap.

Key valuation signals for MEX:SAN1N:

  • Construction In Progress: MXN75,586 Mil
  • GF Value™: MXN2,212.65 vs. price of MXN1,525.85 (31% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the MEX:SAN1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
72GF Score

Get the complete analysis for MEX:SAN1N

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,525.85
Price
MXN2,212.65
GF Value